Skip to main content
SpringerLink
Log in

Switch from 4-valent to 9-valent HPV vaccine cost saving

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. US dollars

Reference

  • Brisson M, et al. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. Journal of the National Cancer Institute 108: No. 1, Jan 2016. Available from: URL: http://doi.org/10.1093/jnci/djv282

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switch from 4-valent to 9-valent HPV vaccine cost saving. PharmacoEcon Outcomes News 739, 26 (2015). https://doi.org/10.1007/s40274-015-2544-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2544-5

Search

Navigation